Deborah Burns
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1932522836
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,481 and has fallen 97.3% since, to $40 in 2025.
Across 293 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$696
- Abbott$543
- Novo Nordisk$422
- Boehringer Ingelheim$320
- Radius Health, Inc.$312
- Dexcom, Inc.$285
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,08699%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 49 | $696 |
| Abbott | 41 | $543 |
| Novo Nordisk | 21 | $422 |
| Boehringer Ingelheim | 17 | $320 |
| Radius Health, Inc. | 14 | $312 |
| Dexcom, Inc. | 15 | $285 |
| Amgen(2 entities) | 14 | $284 |
| AbbVie | 14 | $251 |
| Sanofi-aventis U.S. LLC | 11 | $208 |
| Xeris Pharmaceuticals, Inc. | 11 | $194 |
| Amneal Pharmaceuticals LLC | 9 | $155 |
| Medtronic | 8 | $143 |
| AstraZeneca | 9 | $125 |
| Insulet Corporation | 6 | $122 |
| Zealand Pharma US, Inc. | 5 | $95 |
| Cequr Corporation | 2 | $95 |
| Bayer | 5 | $92 |
| Corcept Therapeutics | 5 | $87 |
| Amryt Pharma Holdings Ltd | 4 | $82 |
| Mannkind Corporation | 4 | $79 |
| GRT US Holding, Inc. | 3 | $65 |
| Alfasigma USA, Inc. | 3 | $46 |
| Ascensia Diabetes Care US Inc. | 2 | $43 |
| Tandem Diabetes Care, Inc. | 3 | $40 |
| Verity Pharmaceuticals Inc. | 2 | $39 |
| Amphastar Pharmaceuticals, Inc. | 2 | $33 |
| Intuity Medical Inc | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Nevro Corp. | 1 | $31 |
| Merck | 2 | $29 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Chiesi USA, Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Vistapharm, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$149
- Wegovy$119
How this compares
$5,111 in reported general payments places this provider in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 96 | $143,235 |
| JardianceEmpagliflozin | 83 | $118,735 |
| TrulicityDulaglutide | 62 | $92,175 |
| OzempicSemaglutide | 46 | $82,084 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $36,691 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $28,271 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $19,178 |
| GenotropinSomatropin | 12 | $11,382 |
| HumalogInsulin Lispro | 23 | $10,229 |
| SynthroidLevothyroxine Sodium | 95 | $10,138 |
| Novolog FlexpenInsulin Aspart | 22 | $6,621 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 37 | $4,321 |
| Levothyroxine Sodium | 218 | $3,397 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $2,844 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $696 | $245,639181 claims |
| Boehringer IngelheimJardiance | $320 | $118,73583 claims |
| Novo NordiskOzempic | $422 | $82,08446 claims |
| AbbVieSynthroid | $251 | $10,13895 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $155 | $3,397218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.